Metall Zug Group Reports 2024 Financial Year Results

Metall Zug Group achieved key milestones in its strategic shift during 2024, showcasing strong financial performance and progress in innovation. The successful formation of the SteelcoBelimed joint venture resulted in a gain of CHF 66.6 million. The group's net sales decreased to CHF 283.4 million from CHF 494.7 million in 2023, affected by the divestment of Belimed and market conditions. Despite this, EBIT rose to CHF 58.0 million. Metall Zug proposes a dividend of CHF 2.00 per type A share and CHF 20.00 per type B share.

The company remains committed to innovation, particularly in ophthalmology, marked by investments in the Haag-Streit Group and the launch of the Metis surgical microscope. Continued investment in R&D underscores this focus, even as the group faces lower sales in some areas.

Looking ahead, despite market uncertainties, Metall Zug is optimistic about long-term growth, banking on strategic positioning and innovation to leverage future economic recovery.